Study analysis · Therapeutic Advances in Neurological Disorders · 2024
Could a fecal transplant reverse Alzheimer's symptoms? A tiny study says yes, but there's a catch.
In a study of just 5 Alzheimer's patients, a fecal transplant from healthy donors was linked to significant memory improvements after 3 months.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a diary of 5 people who got a treatment. It tells us what happened to them, but we can't be sure the treatment caused the changes because there was no comparison group. So we can only say 'these 5 people got better after the treatment' but not 'the treatment made them better.'
What’s the bottom line?
Scientists gave 5 Alzheimer's patients a fecal transplant from healthy donors to see if it could improve their memory and thinking.
How strong is this study?
Imagine a science project with only 5 kids, no one to compare them to, and the teacher knows who got the special snack. That's this study. It's a very small experiment, and we can't trust the results much because there are too many other possible explanations for what happened.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=5)+0.5/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is an uncontrolled case series with only 5 patients, no randomization, no blinding, and no control group. Therefore, it cannot establish cause-effect relationships; it only describes observations without the ability to attribute changes to the intervention.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified based on available information.
No disclosure statements present. Study conducted at hospital dementia and microbiome centers. Small sample size (n=5) and preliminary nature may limit generalizability.
Key takeaways
- 01
After 3 months, patients' memory test scores improved by about 6 points out of 30.
- 02
Their gut bacteria changed: helpful bacteria increased, harmful ones decreased.
- 03
The improvements are noticeable, but the study is tiny and lacks a comparison group, so we can't be sure the transplant caused the change.
Surprising findings
- FMT led to a 6-point improvement on the MMSE (out of 30) in just 3 months — a larger gain than many Alzheimer's drugs show in trials.Typical Alzheimer's medications might slow decline by 1-2 points over a year. Here, improvement was seen in a few months with no drugs.
- After FMT, 'bad' LDL cholesterol increased (100.75 to 127.50 mg/dL) and 'good' HDL decreased (49.75 to 24.75 mg/dL), opposite of what you'd want for heart health.If FMT improves cognition but worsens cholesterol, it raises questions about overall health trade-offs.
Practical takeaways
If you have recurrent C. diff infection and Alzheimer's, talk to your doctor about whether FMT might help both conditions.
This is a single tiny study — FMT is not approved for Alzheimer's. Larger, controlled trials are needed before recommending it.
low confidenceMaintain a healthy gut microbiome through diet (fiber, fermented foods) — while not proven to prevent Alzheimer's, it supports overall health.
This study used FMT from healthy donors, not probiotics or diet changes. Dietary effects may be milder.
medium confidenceWhy this study matters
The poop pill that might boost brainpower
Five Alzheimer's patients with recurrent C. diff infections received fecal microbiota transplants (FMT). After 3 months, their MMSE scores improved by an average of 6 points (from 13 to 18) and MoCA scores by 6.2 points (from 12 to 21). The CDR-SOB, a dementia severity scale, dropped by 3.1 points (from 10 to 5.5). These are clinically meaningful changes.
It hints that modifying gut bacteria could directly impact brain function — a concept that's both fascinating and accessible.
Your gut bugs might control your memory
After FMT, the patients' gut microbiome shifted: beneficial Bacteroidaceae rose from 17% to 33% of bacteria, while potentially harmful Enterococcaceae dropped from 23% to 6%. The Bacteroides genus increased from 0.84% to 38.18% (p=0.047). Alpha diversity also increased significantly (Shannon index p=0.026).
People are increasingly aware of the gut-brain connection, and this provides direct human evidence.
Lipid metabolism genes light up after poop transplant
The study measured 84 lipid metabolism genes and found significant changes in 12 after FMT. Notably, ACAA1 (32.5 vs 29.2 fold change, p=0.0004), EHHADH (19.3 vs 27.4, p=0.016), and B2M (24.5 vs 22.3, p=0.010) were upregulated, while FABP6 was downregulated. This suggests FMT may alter how the brain processes fats.
Links gut bacteria to brain health through lipid metabolism — a concrete mechanism that feels cutting-edge.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 5 Alzheimer's patients a fecal transplant from healthy donors to see if it could improve their memory and thinking.
Research results
After 3 months, patients' memory test scores improved by about 6 points out of 30. Their gut bacteria changed: helpful bacteria increased, harmful ones decreased.
What this means - more context
The improvements are noticeable, but the study is tiny and lacks a comparison group, so we can't be sure the transplant caused the change.
To explore the effects of fecal microbiota transplantation (FMT) on cognitive performance and gut microbiome/lipid metabolism gene expression in Alzheimer's dementia patients.
In a case series of 5 Alzheimer's dementia patients with recurrent Clostridioides difficile infection, FMT was associated with significant cognitive improvements (MMSE +6.0, MoCA +6.2, CDR-SOB -3.1 at 3 months), increased gut Bacteroidaceae and decreased Enterococcaceae, and altered expression of lipid metabolism genes (upregulation of ACAA1, EHHADH, B2M; downregulation of FABP6). No serious adverse effects were reported.
Methods Used
Case series; 5 AD patients with recurrent CDI; FMT via colonoscopy; cognitive assessments (MMSE, MoCA, CDR-SOB) at baseline, 1 month, 3 months; 16S rRNA sequencing of fecal samples; serum RNA qPCR for lipid metabolism genes.
Main Finding
FMT was associated with cognitive improvement and concurrent changes in gut microbiota composition and lipid metabolism gene expression, suggesting a potential therapeutic link between gut microbiome modification and cognitive function in Alzheimer's disease.
Confidence Level
Low due to very small sample size (n=5), lack of control group, and short follow-up (3 months).
Study Flags
Red Flags
- •Very small sample size (n=5)
- •No control group
- •Short follow-up (3 months)
Surprising Findings
FMT led to a 6-point improvement on the MMSE (out of 30) in just 3 months — a larger gain than many Alzheimer's drugs show in trials.
Typical Alzheimer's medications might slow decline by 1-2 points over a year. Here, improvement was seen in a few months with no drugs.
Practical Takeaways
If you have recurrent C. diff infection and Alzheimer's, talk to your doctor about whether FMT might help both conditions.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Case Report
Subject
Lower probability
on the GRADE evidence scale
This study is like a diary of 5 people who got a treatment. It tells us what happened to them, but we can't be sure the treatment caused the changes because there was no comparison group. So we can only say 'these 5 people got better after the treatment' but not 'the treatment made them better.'
No conflicts of interest were detected in this study. No score impact.
Weaknesses
- No randomization
- No control group
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 5 Alzheimer's patients a fecal transplant from healthy donors to see if it could improve their memory and thinking.
Research results
After 3 months, patients' memory test scores improved by about 6 points out of 30. Their gut bacteria changed: helpful bacteria increased, harmful ones decreased.
What this means - more context
The improvements are noticeable, but the study is tiny and lacks a comparison group, so we can't be sure the transplant caused the change.
To explore the effects of fecal microbiota transplantation (FMT) on cognitive performance and gut microbiome/lipid metabolism gene expression in Alzheimer's dementia patients.
In a case series of 5 Alzheimer's dementia patients with recurrent Clostridioides difficile infection, FMT was associated with significant cognitive improvements (MMSE +6.0, MoCA +6.2, CDR-SOB -3.1 at 3 months), increased gut Bacteroidaceae and decreased Enterococcaceae, and altered expression of lipid metabolism genes (upregulation of ACAA1, EHHADH, B2M; downregulation of FABP6). No serious adverse effects were reported.
Methods Used
Case series; 5 AD patients with recurrent CDI; FMT via colonoscopy; cognitive assessments (MMSE, MoCA, CDR-SOB) at baseline, 1 month, 3 months; 16S rRNA sequencing of fecal samples; serum RNA qPCR for lipid metabolism genes.
Main Finding
FMT was associated with cognitive improvement and concurrent changes in gut microbiota composition and lipid metabolism gene expression, suggesting a potential therapeutic link between gut microbiome modification and cognitive function in Alzheimer's disease.
Confidence Level
Low due to very small sample size (n=5), lack of control group, and short follow-up (3 months).
Study Flags
Red Flags
- •Very small sample size (n=5)
- •No control group
- •Short follow-up (3 months)
Surprising Findings
FMT led to a 6-point improvement on the MMSE (out of 30) in just 3 months — a larger gain than many Alzheimer's drugs show in trials.
Typical Alzheimer's medications might slow decline by 1-2 points over a year. Here, improvement was seen in a few months with no drugs.
Practical Takeaways
If you have recurrent C. diff infection and Alzheimer's, talk to your doctor about whether FMT might help both conditions.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Case Report
Subject
Lower probability
on the GRADE evidence scale
This study is like a diary of 5 people who got a treatment. It tells us what happened to them, but we can't be sure the treatment caused the changes because there was no comparison group. So we can only say 'these 5 people got better after the treatment' but not 'the treatment made them better.'
No conflicts of interest were detected in this study. No score impact.
Weaknesses
- No randomization
- No control group
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
Imagine a science project with only 5 kids, no one to compare them to, and the teacher knows who got the special snack. That's this study. It's a very small experiment, and we can't trust the results much because there are too many other possible explanations for what happened.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=5)+0.5/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is an uncontrolled case series with only 5 patients, no randomization, no blinding, and no control group. Therefore, it cannot establish cause-effect relationships; it only describes observations without the ability to attribute changes to the intervention.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified based on available information.
No disclosure statements present. Study conducted at hospital dementia and microbiome centers. Small sample size (n=5) and preliminary nature may limit generalizability.